Aluminum-containing adjuvants have been used over 80 years and play a very important role in many vaccines. However, the mechanism of aluminum-containing adjuvants as well as the problems existing in their application remain uncertain. HPAIV H5N1 arouses people’s attention and anxiety worldwide. Vaccination is an effective control measure. The use of aluminum hydroxide adjuvant will decrease the dosage of antigen whereas the vaccine reaches the same antibody titer. This paper summarizes some recent developments in HPATV H5N1 with aluminium-hydroxide adjuvant, and assesses the prospect of this new adjuvant vaccine.
